Generic Name and Formulations:
Halobetasol propionate 0.05%; crm; oint.
Sun Pharmaceutical Industries
Indications for ULTRAVATE:
Apply a thin layer to affected areas 1–2 times daily; max 50 g/week and 2 consecutive weeks' treatment per course. Discontinue when control is achieved. Do not occlude.
Avoid use near eyes, on face, groin, or axillae. Do not use for diaper dermatitis, rosacea, perioral dermatitis, or on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Treat infection if present; discontinue if infection persists or worsens. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Burning, stinging, itching, dry skin, erythema, skin atrophy, leukoderma, vesicles, rash, pustulation, acne, secondary infections, telangiectasia, urticaria, miliaria; HPA axis suppression (esp. in children).
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age